EE280 Budget Impact (BI) of First-Line (1L) Cemiplimab Monotherapy for Advanced Non-Small Cell Lung Cancer (aNSCLC) with Programmed Cell Death-Ligand 1 (PD-L1) ≥50% in a Large US Health Plan: An Updated Analysis
| Autor: | Quek, RGW, Theriou, C, Smare, C, Keeping, S, Xu, Y, Konidaris, G, LaFontaine, PR, Harnett, J |
|---|---|
| Zdroj: | In Value in Health July 2022 25(7) Supplement:S388-S388 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect